Infants with congenital diaphragmatic hernia often require intensive treatment after birth, have prolonged hospitalizations, and have other congenital anomalies. After discharge from the hospital, they may have long-term sequelae such as respiratory insufficiency, gastroesophageal reflux, poor growth, neurodevelopmental delay, behavior problems, hearing loss, hernia recurrence, and orthopedic deformities. Structured follow-up for these patients facilitates early recognition and treatment of these complications. In this report, follow-up of infants with congenital diaphragmatic hernia is outlined.
MD]) also is suggested for infants with CDH who have chronic lung disease, as described in the "Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections" technical report and policy statement by the American Academy of Pediatrics. 18, 19 Although the incidence of chronic lung disease is 33% to 52% at discharge, most infants who survive CDH have clinical improvement over time. 6, 16, 17 Nevertheless, nearly 50% of adult survivors have impairment on pulmonary function testing. 16 
GASTROESOPHAGEAL REFLUX/FOREGUT DYSMOTILITY
Gastroesophageal reflux or some form of foregut dysmotility occurs in 45% to 90% of infants with CDH. [20] [21] [22] [23] [24] Abnormal hiatal anatomy at the gastroesophageal junction, lack of an angle of His in some patients, and herniation of the stomach into the chest with distortion are possible mechanisms to explain this high incidence of gastroesophageal reflux. Esophageal dilation or ectasia also has been described in some infants with CDH, and as many as 70% of such infants have severe gastroesophageal reflux. 21 The incidence of gastroesophageal reflux also correlates with defect size and need for patch repair. 20, 25 Pulmonary morbidity may be worsened by aspiration associated with gastroesophageal reflux. Importantly, a high incidence of esophagitis in adult survivors with CDH suggests that long-term surveillance is needed. 26 For all patients with CDH, it is important to have a high index of suspicion for gastroesophageal reflux. Antireflux surgery may be an option for patients with failed medical therapy, although the long-term success rate of this procedure has yet to be proven.
GROWTH FAILURE
Many survivors with CDH fail to grow as well as healthy term infants do and require close nutritional surveillance and intervention. 6, 9, 20 Infants with CDH and chronic lung disease often have poor oral feeding skills. Gastroesophageal reflux is common, and oral aversion is frequent; both contribute to growth deficiency. In 1 clinical series, more than 50% of infants with CDH had weight below the 25th percentile. 20 Gastrostomy tube placement was performed in 33% of infants in this series. Van Meurs et al 6 showed that more than 40% of CDH survivors had weight below the 5th percentile at 2 years of age. Gastrostomy tube feeding is suggested by some experts who hypothesize that nasogastric or orogastric tube feeding impairs oral feeding. Others suggest use of nasogastric or orogastric tube feeding for a period of time, especially when success with oral feeding is anticipated within several months. Despite controversy about the most appropriate mode of feeding the infant with CDH at discharge, almost 33% do not orally feed enough fluid volume to support growth and receive feedings through nasogastric or gastrostomy tubes. 6, 20 Early recognition and intervention is essential for optimizing both somatic and alveolar growth and long-term outcomes for infants with CDH.
NEUROCOGNITIVE DELAY AND BEHAVIORAL DISORDERS
Significant developmental delay and behavioral disorders have been reported for a large number of infants with CDH. The infant with a large diaphragmatic defect or need for ECMO is at greatest risk. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Nobuhara et al 27 reported developmental delay in more than 33% of their CDH survivors. McGahren et al 30 described neurologic abnormalities in 67% of infants with CDH who were treated with ECMO compared with 24% of infants with CDH who were not as ill and did not receive ECMO.
The critical illness and physiologic disruption of highrisk infants with CDH places them at risk of neurologic and developmental disabilities. Many infants who present with symptoms of CDH soon after birth are clinically unstable and hypoxemic and require high levels of extraordinary life support such as ECMO and other invasive therapies. Although severity of illness is most predictive of long-term outcome, complications associated with invasive therapies may contribute to morbidity in CDH survivors. In a study by Bernbaum et al 37 of survivors receiving ECMO, infants with CDH treated with ECMO had a higher risk of significant neurodevelopmental delays than did infants without CDH. The higher risk of disability in ECMO-treated survivors with CDH compared with ECMO-treated survivors without CDH suggests that at least 3 potential factors may contribute to neurodevelopmental disability in infants with CDH: (1) an intrinsic neurologic abnormality, (2) greater number and severity of morbidities that impair development in infants who require ECMO, (3) and a greater number of ECMO-associated complications.
HEARING LOSS
Sensorineural hearing loss has been described in a number of case series of CDH survivors 27, 28, 33, 35 and seems to occur in infants regardless of whether they were treated with ECMO. The cause remains unknown, but it is speculated to be related to treatments for respiratory failure (such as hyperventilation, ototoxic medications, or neuromuscular blockade). 38 Severe hypoxemia, prolonged ventilation, and ECMO also are risk factors. Approximately half of infants with initially normal hearing assessments develop hearing loss later in infancy. [39] [40] [41] HERNIA RECURRENCE Recurrent diaphragmatic hernias have been reported in 8% to 50% of patients with CDH. The single-most important predictor of hernia recurrence is the presence of a large defect that requires a patch to repair. 2, 6, 42, 43 Recurrences can present from months to years after the initial hospitalization, or the patient can remain asymptomatic. Detection of recurrences may be discovered incidentally on chest radiographs performed for surveillance or other reasons. 6, 43 The lifetime risk of recurrence for a patient with a patch repair is unknown. 21% to 48%. Many of them are mild and do not require surgical intervention. Scoliosis also has been found in these patients, with an incidence of 10% to 27%. 27, 44 The incidence of both of these morbidities is higher in patients who have large defects and a patch repair. Periodic and regular follow-up is suggested to detect and prevent development of functionally significant deformities from developing.
OTHER CONGENITAL ABNORMALITIES
Additional congenital anomalies are present in approximately 40% of infants with CDH. [45] [46] [47] [48] Congenital heart lesions account for nearly two thirds of these anomalies and have a major effect on risk of mortality. 45, 48 [49] [50] [51] [52] To emphasize the importance of follow-up for specific morbidities associated with CDH, additional suggestions are provided (Table 1) . These are most applicable to children with extraordinary medical and surgical complications associated with CDH and should be individualized depending on the specific needs of each infant.
